Close

News Releases

News Release

Meridian Bioscience Awarded NIH Contract for Production of Experimental Vaccines

August 7, 2007 at 10:47 AM EDT

CINCINNATI--(BUSINESS WIRE)--Aug. 7, 2007--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that its wholly owned subsidiary, Meridian Life Science, Inc. (MLS) was awarded a five year contract (base year plus 4 option years) having a value of up to $12.2 million by the National Institutes of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Meridian will manufacture up to 10 clinical experimental vaccines per year at its biopharmaceutical facility located in Memphis, TN. Meridian will be working closely with the Laboratory of Infectious Diseases (LID) of the NIAID, which has a long history of vaccine development and identification of new agents of viral diseases.

The contract requires production and safety testing of experimental non-influenza and influenza virus vaccines and other vaccine-related products for use in humans. Meridian will be manufacturing suspensions of viruses that have been shown by evaluation in vitro and in vivo to be promising candidates for use in vaccination of humans. Meridian will also be preparing suspensions of wild type viruses that are needed for challenge studies to evaluate effectiveness of immunoprophylaxis or in pathogenesis studies. The scope of the contract also includes the manufacture and qualification of Master Cell Lines for use in the production of such viruses or for other uses as directed by the NIAID.

This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272200700040C.

Richard L. Eberly, President, Meridian Life Science, Inc., commented, "We are pleased to continue our collaboration with the NIH to include the production of viral vaccines and challenge materials for use in human clinical studies. The LID of the NIAID/NIH is one of the premier vaccine development laboratories in the world. Being selected for this program is consistent with our core strengths in cell culture, virology, and immunology and demonstrates our commitment to high quality manufacturing of clinical biologics. Through collaboration with the LID of the NIAID/NIH, we are hopeful that many of these experimental vaccines will ultimately be used for the prevention of viral diseases in humans."

FORWARD LOOKING STATEMENTS

The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements which may be identified by words such as "estimates", "anticipates", "projects", "plans", "seeks", "may", "will", "expects", "intends", "believes", "should" and similar expressions or the negative versions thereof and which also may be identified by their context. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. The Company assumes no obligation to publicly update any forward-looking statements. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following: Meridian's continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian's competition. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Costs and difficulties in complying with laws and regulations administered by the United States Food and Drug Administration can result in unanticipated expenses and delays and interruptions to the sale of new and existing products. Changes in the relative strength or weakness of the U.S. dollar can change expected results. One of Meridian's main growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses successfully integrated into Meridian's operations. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our Form 10-K contains a list of uncertainties and risks that may affect the financial performance of the Company.

Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian's diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company's shares are traded through NASDAQ's Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.

CONTACT: Meridian Bioscience, Inc.
John A. Kraeutler, President, 513-271-3700

SOURCE: Meridian Bioscience, Inc.